THB001

Phase 1Small molecule

TThird Harmonic Bio, Inc.

THB001 is one of 8 small molecule programs targeting Cold Urticaria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cold UrticariaActive, not recruiting

Cold UrticariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Cold Urticaria

#DrugCompanyPhaseTrials

Clarinex

OOrganon and Co

Approved

2 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 3

Xolair

Roche

Phase 2

1 4

Arcalyst

KKiniksa Pharmaceuticals (UK), Ltd.

Phase 2

—5

Bilaxten

MMenarini International Operations Luxembourg SA

Phase 2

—6

Non Sedating H1-Antihistamine

Sanofi

Phase 3

1 7

RUPATADINE

JJ. Uriach and Company

Phase 2

1 8

THB001

TThird Harmonic Bio, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cold Urticaria1 trial

A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Terminated·TThird Harmonic Bio, Inc.·Phase 1·NCT05510843·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for THB001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — THB001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for THB001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Harmonic Bio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThird Harmonic Bio, Inc.

THB001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cold Urticaria1 trial

References

Drug Info

Quick Facts

Related News